Major players such as Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Divi’s Laboratories, Aurobindo Pharma, Lupin, and Biocon faced market volatility.

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

U.S. President Donald Trump on Wednesday slapped 25% tariffs on Indian goods, along with an unspecified penalty tied to energy and defence purchases from Russia — a move that, if enforced, could erode ...

Biocon Biologics on Wednesday announced the appointment of Deepali Naair as Global Head Brand & Corporate Communications, ...

Naair will lead Biocon Biologics' global brand and corporate communications strategy as part of its executive team, reporting ...

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...